相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma (vol 159, pg 496, 2022)
[Anonymous]
CHEST (2023)
Biologics in the treatment of asthma in children and adolescents
Leonard B. Bacharier et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)
Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study
John C. Thelen et al.
RESPIRATORY MEDICINE (2023)
Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy
Hiroyuki Nagase et al.
ALLERGOLOGY INTERNATIONAL (2023)
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
Andrew Menzies-Gow et al.
LANCET RESPIRATORY MEDICINE (2023)
Definitions of non-response and response to biological therapy for severe asthma: a systematic review
Ekaterina Khaleva et al.
ERJ OPEN RESEARCH (2023)
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
Nicola A. Hanania et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2023)
Eosinophilic granulomatosis with polyangiitis: A review
J. P. E. White et al.
AUTOIMMUNITY REVIEWS (2023)
New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis
Ilja Striz et al.
CLINICAL SCIENCE (2023)
Imaging-derived biomarkers in Asthma: Current status and future perspectives
Esther Pompe et al.
RESPIRATORY MEDICINE (2023)
Severe asthma clinical remission after biologic treatment with anti-IL4/ IL13: A real-life experience
Andrea Portacci et al.
RESPIRATORY MEDICINE (2023)
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus
Giorgio Walter Canonica et al.
Journal of Allergy and Clinical Immunology-In Practice (2023)
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
Jonathan Corren et al.
ALLERGY (2022)
A rational approach to compare and select biologic therapeutics in asthma
Eileen Wang et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2022)
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
Michael E. Wechsler et al.
LANCET RESPIRATORY MEDICINE (2022)
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
Andrew N. Menzies-Gow et al.
JOURNAL OF ASTHMA AND ALLERGY (2022)
Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations
Marek Lommatzsch et al.
ALLERGY (2022)
Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study
Yen Chung et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2022)
Severe asthma in children: Description of a large multidisciplinary clinical cohort
Maria Forero Molina et al.
PEDIATRIC PULMONOLOGY (2022)
Sub-stratification of type-2 high airway disease for therapeutic decision-making: A 'bomb' (blood eosinophils) meets 'magnet' (FeNO) framework
Simon Couillard et al.
RESPIROLOGY (2022)
Understanding the Cellular Sources of the Fractional Exhaled Nitric Oxide (FeNO) and Its Role as a Biomarker of Type 2 Inflammation in Asthma
Jose M. Escamilla-Gil et al.
BIOMED RESEARCH INTERNATIONAL (2022)
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
Michael E. Wechsler et al.
LANCET RESPIRATORY MEDICINE (2022)
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis
Michael E. Wechsler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
How to Choose the Correct Drug in Severe Pediatric Asthma
Andrew Bush
FRONTIERS IN PEDIATRICS (2022)
Heterogeneous Condition of Asthmatic Children Patients: A Narrative Review
Cristiano Caruso et al.
CHILDREN-BASEL (2022)
Biologics and airway remodeling in severe asthma
Gilda Varricchi et al.
ALLERGY (2022)
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis
Ayobami Akenroye et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Severe pediatric asthma therapy: Dupilumab
Giuliana Ferrante et al.
FRONTIERS IN PEDIATRICS (2022)
REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma
Charles Pilette et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)
Do not forget asthma comorbidities in pediatric severe asthma!
Lucia Ronco et al.
FRONTIERS IN PEDIATRICS (2022)
Severe Pediatric Asthma Therapy: Mepolizumab
Nicola Ullmann et al.
FRONTIERS IN PEDIATRICS (2022)
Biological Therapy of Severe Asthma and Nasal Polyps
Agamemnon Bakakos et al.
JOURNAL OF PERSONALIZED MEDICINE (2022)
Biologic Therapies in Pediatric Asthma
Evanthia P. Perikleous et al.
JOURNAL OF PERSONALIZED MEDICINE (2022)
Integrated systems modeling of severe asthma: Exploration of IL-33/ST2 antagonism
Kapil Gadkar et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2022)
Airway autoimmunity, asthma exacerbations, and response to biologics
Carmen Venegas Garrido et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2022)
Scientific journey to the first FDA-approved drug for eosinophilic esophagitis
Marc E. Rothenberg
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma
Nicola A. Hanania et al.
WORLD ALLERGY ORGANIZATION JOURNAL (2022)
Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
Anne-Noelle Frix et al.
ERJ OPEN RESEARCH (2022)
Biologicals in atopic disease in pregnancy: An EAACI position paper
Birgit Pfaller et al.
ALLERGY (2021)
EAACI Biologicals Guidelines-Recommendations for severe asthma
Ioana Agache et al.
ALLERGY (2021)
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
Liam G. Heaney et al.
LANCET RESPIRATORY MEDICINE (2021)
Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies
Jean Bousquet et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
The relationship between FENO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma
Andrew P. Hearn et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
Michael E. Wechsler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics
Molly M. Jeffery et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma
Katrien Eger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score
Luis Perez de Llano et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach
Kazuki Hamada et al.
JOURNAL OF ASTHMA AND ALLERGY (2021)
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Andrew Menzies-Gow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
Joseph K. Han et al.
LANCET RESPIRATORY MEDICINE (2021)
Asthma biologics Real-world effectiveness, impact of switching biologics, and predictors of response
Farrukh Abbas et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)
Severe asthma exacerbations in the United States: Incidence, characteristics, predictors, and effects of biologic treatments
Jennifer Trevor et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)
Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP
Ignaz Briegel et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Defining a Severe Asthma Super-Responder: Findings from a Delphi Process
John W. Upham et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
Joanne E. Kavanagh et al.
CHEST (2021)
Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort
Jennifer A. Namazy et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management
Eugene R. Bleecker et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Trends and Disparities in Asthma Biologic Use in the United States
Jonathan W. Inselman et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Characteristics and treatment regimens across ERS SHARP severe asthma registries
Job J. M. H. van Bragt et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma
Ioana Agache et al.
ALLERGY (2020)
An expert consensus framework for asthma remission as a treatment goal
Andrew Menzies-Gow et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort
Clairelyne Dupin et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety
David Price et al.
EUROPEAN RESPIRATORY REVIEW (2020)
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
Tim Harrison et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling
Grzegorz Kardas et al.
FRONTIERS IN IMMUNOLOGY (2020)
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Predictors of response toanti-IL-5biologics
Parameswaran Nair
RESPIROLOGY (2020)
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
Florence Roufosse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy
Giovanna Elisiana Carpagnano et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2020)
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
Thomas B. Casale et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
CT and Functional MRI to Evaluate Airway Mucus in Severe Asthma
Sarah Svenningsen et al.
CHEST (2019)
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018
Karen M. MacDonald et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Severe asthma in children-a review of definitions, epidemiology, and treatment options in 2019
Husam Ahmed et al.
PEDIATRIC PULMONOLOGY (2019)
Treatment of severe persistent asthma with IL-6 receptor blockade
Brittany Esty et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Toward clinically applicable biomarkers for asthma: An EAACI position paper
Zuzana Diamant et al.
ALLERGY (2019)
The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
Kenneth R. Chapman et al.
ALLERGY (2019)
Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis
Rahul Shrimanker et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study
Sandhya Khurana et al.
CLINICAL THERAPEUTICS (2019)
Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype
Atul Gupta et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert et al.
LANCET (2019)
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
Sumita Khatri et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
William W. Busse et al.
LANCET RESPIRATORY MEDICINE (2019)
Immunological biomarkers in severe asthma
Dharani Narendra et al.
SEMINARS IN IMMUNOLOGY (2019)
Interleukin-5 in the Pathophysiology of Severe Asthma
Corrado Pelaia et al.
FRONTIERS IN PHYSIOLOGY (2019)
Parasitic (Helminthic) Infection While on Asthma Biologic Treatment: Not Everything Is What It Seems
Laren D. Tan et al.
JOURNAL OF ASTHMA AND ALLERGY (2019)
Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma
Maria del Carmen Vennera et al.
THORAX (2018)
Managing Asthma in Pregnancy (MAP) trial: FENO levels and childhood asthma
Matthew Morten et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature
Timm Volmer et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis
Imran H. Iftikhar et al.
LUNG (2018)
Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials
Y. Cabon et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2017)
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
M. E. Wechsler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison
Sarah M. Cockle et al.
RESPIRATORY MEDICINE (2017)
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Njira Lugogo et al.
CLINICAL THERAPEUTICS (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
Dominick E. Shaw et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
The prevalence of severe refractory asthma
Pieter-Paul W. Hekking et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
Jasvinder A. Singh et al.
LANCET (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
Type 2 inflammation in asthma - present in most, absent in many
John V. Fahy
NATURE REVIEWS IMMUNOLOGY (2015)
Importance of concomitant local and systemic eosinophilia in uncontrolled asthma
Florence Nicole Schleich et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
M. Molimard et al.
RESPIRATORY MEDICINE (2014)
Exploring the Effects of Omalizumab in Allergic Asthma An Analysis of Biomarkers in the EXTRA Study
Nicola A. Hanania et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Lebrikizumab Treatment in Adults with Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
After 6 years with Xolair; a 3-year withdrawal follow-up
A. Nopp et al.
ALLERGY (2010)
The significance of OX40 and OX40L to T-cell biology and immune disease
Michael Croft et al.
IMMUNOLOGICAL REVIEWS (2009)
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma
Patrick Flood-Page et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Predicting and evaluating response to omalizumab in patients with severe allergic asthma
J. Bousquet et al.
RESPIRATORY MEDICINE (2007)